Navigation Links
Arbitration Panel Issues Ruling in Distribution Dispute
Date:7/25/2008

WALTHAM, Mass., July 25 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (Amex: IMA), a leading provider of rapid diagnostic products and health management services, announced that it received today a decision from an arbitration tribunal. That decision, directed at Inverness' Binax subsidiary, awards Binax's distributor in Spain and Portugal approximately $13.8 million, including interest and arbitration related expenses. While Inverness is reviewing the decision and will evaluate its next steps, the terms of the distribution agreement provide limited remedies to Inverness related to the tribunal's decision.

Inverness will record an after tax charge of approximately $8.6 million or $0.10 per diluted share related to the decision in its earnings for the second quarter of 2008, which are scheduled to be released on July 29, 2008.

About Inverness

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life. A global leader in rapid point-of-care diagnostics, Inverness' products, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts. For more information about Inverness Medical Innovations, please visit http://www.invernessmedical.com.

Statement under the Private Securities Litigation Reform Act

This press release contains forward-looking statements within the meaning of the federal securities laws. Actual results may differ materially due to numerous factors, including without limitation, the demand for Inverness' current and future products; the ability of Inverness to efficiently manufacture those products and the risks and uncertainties described in Inverness' periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
2. Expert Consensus Panel Recommendation for Incorporating Lp-PLA2 Testing into Cardiovascular Disease Risk Assessment Guidelines
3. Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination
4. Paul Capital Healthcare Leads Panel on Strategic Financing
5. WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents
6. DuPont Strengthens Commitment to Responsible Science with New Biotech Advisory Panel Members
7. BioMS Medical to Participate in Speciality Panel Session at BioFinance 2008
8. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
9. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Advanced Life Sciences to Host Conference Call to Discuss Announcement Made Yesterday by FDA to Conduct Advisory Panel on CAP Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Summit for Stem Cell has ... development of a patient-specific stem cell therapy for the treatment of Parkinson’s disease. The ... Jeanne Loring at The Scripps Research Institute in San Diego, CA. , ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... support for Connecticut's innovative, growing companies, today announced the launch of VentureClash ... technology (fintech) companies. , “VentureClash looks to attract the best early-stage ...
(Date:4/27/2016)... ... April 27, 2016 , ... ... testing technology at the Spring 2016 Marijuana Business Conference and Expo. Shimadzu’s high-performance ... solvents, heavy metals, and more. Expo attendees can stop by booth 1021 to ...
(Date:4/27/2016)... ... April 27, 2016 , ... The Board of ... appointment of John Tilton as Chief Commercial Officer.  Mr. Tilton joined Biohaven from ... founding commercial leaders responsible for the commercialization of multiple orphan drug indications. ...
Breaking Biology Technology:
(Date:3/14/2016)... March 14, 2016 NXTD ) ("NXT-ID" ... commerce market, announces the airing of a new series of ... week of March 21 st .  The commercials will air ... popular Squawk on the Street show. --> NXTD ... growing mobile commerce market, announces the airing of a new ...
(Date:3/11/2016)... 11, 2016 --> ... report "Image Recognition Market by Technology (Pattern Recognition), by ... by Deployment Type (On-Premises and Cloud), by Industry Vertical ... by MarketsandMarkets, the global market is expected to grow ... Billion by 2020, at a CAGR of 19.1%. ...
(Date:3/9/2016)... March 9, 2016 This BCC Research report ... of the RNA Sequencing (RNA Seq) market for the ... instruments, tools and reagents, data analysis, and services. ... of the RNA-Sequencing market such as RNA-Sequencing tools and ... main factors affecting each segment and forecast their market ...
Breaking Biology News(10 mins):